PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.

doi:10.1016/j.ejca.2017.12.028

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2018

Vogel Arndt, Kasper Stefan, Bitzer Michael, Block Andreas, Sinn Marianne, Schulze-Bergkamen Henning, Moehler Markus, Pfarr Nicole, Endris Volker, Goeppert Benjamin, Merx Kirsten, Schnoy Elisabeth, Siveke Jens T, Michl Patrick, Waldschmidt Dirk, Kuhlmann Jan, Geissler Michael, Kahl Christoph, Evenkamp Ralph, Schmidt Torben, Kuhlmann Alexander, Weichert Wilko, Kubicka Stefan

Abstract excerpt

BACKGROUND: Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. PATIENTS AND METHODS: Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Deoxycytidine

Share to Disease-Free Survival

Share to Gemcitabine

Share to Germany

Share to Isocitrate Dehydrogenase

Share to Panitumumab

Source

Open in PubMed

Identifiers

PMID: 29413685
DOI: 10.1016/j.ejca.2017.12.028

Genes

EGFR
KRAS
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer-a randomised biomarker-driven clinical phase II AIO study.PMID 29413685Read ↗

Randomized Phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable biliary tract cancer without KRAS exon 2 mutations.Semantic proximity Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.Semantic proximity Read ↗

Rational development of combination therapies for biliary tract cancers.Semantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Chemotherapy and targeted therapy for advanced biliary tract cancers：An umbrella reviewSemantic proximity Read ↗

Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.Semantic proximity Read ↗

New Treatment Options for Advanced Biliary Tract Cancer.Semantic proximity Read ↗

Molecular profiling of biliary tract cancer: a target rich diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.